Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Arsenic Trioxide in Advanced Esophageal Adenocarcinoma
NCT00061958Phase 2Terminated
- Sponsor
- National Cancer Institute
- Start
- Jun 2003
- Primary completion
- Apr 2005
- Modality
- DNA Intercalators/Alkylators
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of arsenic trioxide in esophageal adenocarcinoma (EAC) and gastroesophageal junction adenocarcinoma, sponsored by National Cancer Institute. Primary endpoint: Objective Response Rate at 8 weeks. Started Jun 2003; status: terminated.
02
Drugs
arsenic trioxide
03
Conditions
esophageal adenocarcinoma (EAC)gastroesophageal junction adenocarcinoma
Beyond the preview
Go deeper on NCT00061958.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00061958.